RME:F:F-ResMed Inc (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 212.3

Change

-14.90 (-6.56)%

Market Cap

USD 33.80B

Volume

53.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-2.05 (-0.47%)

USD 158.73B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

-3.00 (-2.88%)

USD 95.76B
ESL:F EssilorLuxottica Société ano..

-0.30 (-0.15%)

USD 95.72B
BOX:F Becton Dickinson and Company

-3.00 (-1.43%)

USD 61.57B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-2.00 (-1.64%)

USD 42.88B
HYB:F HOYA Corporation

-1.65 (-1.33%)

USD 42.41B
RMEA:F Resmed Inc DRC

-0.60 (-2.68%)

USD 33.02B
CBH:F COLOPLAST SP.ADR 1/10 DK1

-0.20 (-1.61%)

USD 27.61B
CBHD:F Coloplast A/S

-4.50 (-3.56%)

USD 27.31B
QS50:F STRAUM.HLD.UNSP.ADR/1/10

N/A

USD 20.01B

ETFs Containing RME:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.18% 88% B+ 88% B+
Dividend Return 1.29% 41% F 15% F
Total Return 36.47% 78% C+ 80% B-
Trailing 12 Months  
Capital Gain 57.43% 91% A- 91% A-
Dividend Return 1.85% 42% F 17% F
Total Return 59.29% 81% B- 84% B
Trailing 5 Years  
Capital Gain 77.09% 95% A 81% B-
Dividend Return 3.71% 32% F 12% F
Total Return 80.81% 84% B 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.46% 68% D+ 62% D
Dividend Return 6.83% 60% D- 56% F
Total Return 0.37% 33% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 25.73% 52% F 51% F
Risk Adjusted Return 26.55% 63% D 54% F
Market Capitalization 33.80B 93% A 94% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.